U.S. market Closed. Opens in 1 day 16 hours 26 minutes

CTNM | Contineum Therapeutics, Inc. Class A Common Stock Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-31
Revenue50.00MN/AN/A
Cost of RevenueN/A329.00KN/A
Gross Profit50.00M-329.00KN/A
Operating Expenses33.92M22.39M28.65M
Selling, General & Admin6.32M5.50M6.29M
Research & Development27.60M16.89M22.36M
Other Operating ExpensesN/A-92.00K-91.00K
Operating Income16.08M-22.72M-28.65M
Other Expenses / Income7.09M-1.53M-354.00K
Before Tax Income23.17M-24.25M-29.00M
Income Tax Expenses450.00KN/A241.00K
Net Income22.72M-24.25M-29.00M
Interest Expenses208.00K388.00K332.00K
Basic Shares Outstanding16.67M25.13M16.67M
Diluted Shares Outstanding17.76M25.13M17.76M
EBITDA23.57M-23.54M-28.34M
EBITDA Margin47.15%0.00%0.00%
EBIT23.38M-23.86M-28.43M
EBIT Margin46.76%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙